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were conducted in South America (92%), particularly in Brazil (64%). The mean age 
was 60 ± 9 years and the mean ejection fraction was 36 ± 9%. Most studies evalu-
ated more than one etiology (79%) but the etiology more studies exclusively was 
Chagas disease (13%). The incidence of HF ranged from 199 to 557 cases per 100,000 
person-years and the pooled prevalence was 1%, being higher in older populations. 
Hospitalization rates in patients with HF ranged from 28 to 31% at different time 
points, and the median length of stay was 7.0 days. In-hospital mortality was 11.7%, 
being higher in patients with worse ejection fraction, with ischemic and with Chagas 
disease. Mortality at one year was 24.52% (95%CI 19.42 to 30.02). ConClusions: 
This SR of HF in Latin America, could help decision-makers to design better preven-
tive strategies, and guide effective patient-centered care.
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objeCtives: To estimate the economic impact of the use of alteplase versus best 
supportive care (BSC) in patients with acute ischemic stroke in Mexico. Methods: 
A decision tree cost-effectiveness (CE) model assessed the treatment related cost for 
Alteplase and BSC related to two mayor disease branches: with or without intrac-
ranial hemorrhage. Terminal nodes in each arm included death, independent- or 
dependent survival. Published results of head to head clinical trials efficacy inputs 
populated the model. Treatment algorithm was obtained from the local governmen-
tal guide. Public institutional direct medical costs (2014 purchases and price tabula-
tors) where retrieved to adopt the national health system perspective. Governmental 
databases and 2014 purchases provided the epidemiology inputs. A five year fore-
cast estimated the budget impact of the use of alteplase versus BSC. Results: 
7,976 patients yearly were calculated to require medical attention due to an acute 
ischaemic stroke in Mexico. Mean saving per patient in the alteplase versus BSC 
arm was estimated to be US$67,142.76 at the CE model. 16% versus 12% positive 
response to treatment was seen at alteplase and BSC arms respectively. Starting 
at a 4% Market share level, and assuming an increasing share at a 1% rate per year, 
potential savings for new cases at year five (8% share) were estimated to be as high 
as US$35,342,527.00. ConClusions: At a better response rate with lower costs of 
treatment, alteplase was estimated to be a cost-saving therapy versus BSC in a CE 
model. In a five year budget impact analysis, this novel alternative showed to bring 
potential savings in the public Mexican institutional context versus BSC. The savings 
proportionally increase with a higher levels of patients treated and market share.
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objeCtives: To estimate the economic impact of the use of tenecteplase versus 
streptokinase in patients with acute myocardial infarction (AMI). Methods: A 
decision tree cost-effectiveness (CE) model assessed the treatment related cost 
for tenecteplase and streptokinase related to two mayor disease branches: with or 
without acute reperfusion therapy. In the reperfusion arm, terminal nodes included 
none or one or more complications; those without therapy could only survive or 
die. Complications comprised death, reinfarction, cardiac failure, cerebral infarc-
tion, minor and mayor bleedings and intracranial hemorrhage. Published results 
of head to head clinical trials or indirect comparisons efficacy inputs populated 
the model. Treatment algorithm was obtained from the local governmental guide. 
Public institutional direct medical costs (2014 purchases and price tabulators) where 
retrieved to adopt the national health system perspective. Governmental databases 
and 2014 purchases provided the epidemiology inputs. A five year forecast esti-
mated the budget impact of the use of tenecteplase versus streptokinase. Results: 
20,002 patients yearly were calculated to require medical attention due to an AMI in 
Mexico. Mean saving per patient in the tenecteplase versus the streptokinase arm 
was estimated to be US$1,920.00 at the CE model. 98% versus 93% positive response 
to treatment was seen at tenecteplase and streptokinase arms respectively. Starting 
at a 3% Market share level, and assuming an increasing share at a 3% rate per year, 
potential savings for new cases at year five (15% share) were estimated to be as high 
as US$16,371,461.00. ConClusions: At a better response rate with lower costs of 
treatment, tenecteplase was estimated to be a cost-saving therapy versus strepto-
kinase in a CE model. In a five year budget impact analysis, this novel alternative 
showed to bring potential savings in the public Mexican institutional context ver-
sus streptokinase. The savings proportionally increase with a higher market share.
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objetivos: Analisar o impacto orçamentário da do everolimo, sirolimo e tac-
rolimo para transplantados cardíacos no Sistema Público de Saúde do Brasil 
(SUS). Métodos: Para estimar a população que realizou transplante cardíaco no 
Brasil passível de utilizar esses medicamentos, desenhou-se coorte hipotética a 
partir do número de transplantes de coração no Brasil entre 1999 e 2013, obtido por 
meio do Sistema de Informações do SUS, e da taxa anual de sobrevida ao longo de 
15 anos, extraída de estudo de coorte multicêntrico internacional. Considerando 
que os medicamentos em análise estão disponíveis no SUS para transplantados 
Rankin Scale (mRs) was 3.8 , SD 0.8, 95 CI [3.4 - 4.1 ]. At day 15 follow-up NIHSS, 
was 11; SD 4.5; 95 CI [9.3 - 12.8 ]; mean mRs score was 1.9, SD 0.7, 95 CI [1.7 - 2.2 ], 
(p = 0.000 and 0.000 respectively).Only one patient report nightmares as adverse 
event. ConClusions: The current study demonstrate that cerebrolysin treatment 
improves functional outcome safely in Mexican patients with ASIS. Future double-
blind studies with larger sample sizes will further help to explore causal benefits 
of this drug in stroke outcome.
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objeCtives: To review trials of physician-centered interventions to reducing sys-
tolic blood pressure (SBP) and diastolic blood pressure (DBP). Methods: Systematic 
review and meta-analysis. We searched MEDLINE, EMBASE and Cochrane Central for 
all-language articles up to September 2014. We included randomized controlled trial 
(RCT) of physician-centered interventions for hypertension compared with usual 
care or minimal intervention in primary care patients. Data were pooled using a 
random effect meta-analysis model. The effect were expressed as the weighted 
mean difference (WMD). Results: Twenty-five trials of 7595 citation were included. 
Seventeen studies were cluster RCT, one trial was factorial and cluster trial. The 
remaining seven studies were randomized at individual patient level; five of them 
used a two-by-two factorial design. Two studies did not report any estimates of vari-
ance. Overall, 23 trials (43.489 participants) was contribute to the meta-analysis. The 
physician-centered intervention were categorized as computer decision support (6 
trials), stepped treatment algorithm (6), Medical Education (4), Audit and feedback 
(3) and Multifaceted (4). Methodological quality of included studies was rather low. 
Only interventions that the main focus were stepped treatment algorithm showed 
significant reductions in blood pressure: weighted mean difference, systolic - 4.2 
mmHg; 95% confidence interval -5.3 to -3.2; I², 80.1% and diastolic -1.6 mmHg; 95% 
confidence interval -2.8 to -0.49; I². 93.4%. For the remaining five categories did not 
show to reducing blood pressure. Subgroup analyses by study design explained 
considerable heterogeneity in stepped treatment algorithm effect. ConClusions: 
Physician-centered interventions based in stepped treatment algorithm showed 
significantly reductions of systolic and diastolic blood pressure. The magnitude of 
reduction in blood pressure is likely to prevent stroke and death in patients.
PCV5
AntIPSyChOtIC ExPOSURE AnD RISk Of StROkE: A SyStEmAtIC REVIEw 
AnD mEtA-AnALySIS Of OBSERVAtIOnAL StUDIES
Hsu W1, Esmaily-Fard A2, Lee C3
1National Taiwan University Hospital, Taipei City, Taiwan, 2The University of Texas MD Anderson 
Cancer Center, Houston, TX, USA, 3National Taiwan University Hospital, Yunlin Branch, Douliou, 
Taiwan
bACkgRound: Use of antipsychotic medications has been associated with 
increased risk of cerebrovascular events; however, this association remains ques-
tionable given conflicting evidence in the literature. objeCtives: We conducted 
a systematic review and meta-analysis to determine the risk of stroke with the 
use of antipsychotic medications. Methods: All articles published between 
1970 and February 2015 were identified by comprehensively searching PubMed, 
MEDLINE and EMBASE without language restrictions. Observational studies com-
paring stroke outcomes in antipsychotic patients with non-users were selected. 
Two authors independently extracted study characteristics and indicators of study 
quality. Newcastle-Ottawa Scale was adopted to assess risk of bias. Pooled odd 
ratios (ORs) and heterogeneity (I2) were estimated on the basis of random effects 
models. Results: We identified 22 potentially relevant studies from 1,171 citations. 
Of these, 9 studies (3 cohort, 5 case–control and 1 case-case-time-control) with a 
total of 155,789 subjects and 10,203 cases of stroke were eligible for final analysis. 
Use of antipsychotics was associated with a significantly higher risk of developing 
stroke [OR 1.57, 95% confidence interval (CI) 1.29-1.98, I2 = 92.4%]. The pooled OR 
for stroke was 1.58 [95% CI 1.01-2.49, I2 = 68.4%] with exposure to conventional 
antipsychotics and 1.06 [95% CI 0.59-1.89, I2 = 56.2%] with exposure to atypical 
antipsychotics. Subgroup analysis of conventional antipsychotics showed elderly 
patients over 64 years old were at lower risk for stroke [OR 1.37, 95% CI 0.87-2.17, I2 
= 64.5%]. Due to limited data on individual agents, only Risperidone was evaluated 
in the subgroup analysis of atypical antipsychotics. Risperidone users were less 
likely to develop stroke than non-users of antipsychotics [OR 0.63, 95% CI 0.33-1.17, 
I2 = 55.2%]. ConClusions: Exposure to conventional antipsychotic was associated 
with a significant increase in stroke risk. Nonetheless, use of atypical antipsychotics 
revealed lower risk of stroke. Given heterogeneity among eligible studies, additional 
research is needed.
PCV6
BURDEn Of hEARt fAILURE In LAtIn AmERICA: A SyStEmAtIC REVIEw AnD 
mEtA-AnALySIS
Ciapponi A, Bardach A, Calderón M, Alcaraz A, Matta MG, Chaparro M, Soto N
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina
objeCtives: Heart failure (HF) is a common clinical syndrome representing the 
end-stage of several cardiac diseases. Our objective was to estimate the burden of 
heart failure in Latin America. Methods: A systematic review and meta-analysis 
was performed. We searched in MEDLINE, EMBASE, LILACS, and CENTRAL from 
January 1994 to June 2014. We included non-comparative data from experimental 
and observational studies. No language restriction was imposed. We included stud-
ies with samples of at least 50 participants of 18 years of age or older with HF. The 
outcomes analyzed were incidence, prevalence, hospitalization rates and case fatal-
ity ratios of HF at different time points, length of stay and mortality. Results: The 
search retrieved 4792 references of which 143 studies were finally included. Most 
